Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?

Data mining on electronic health records (EHRs) has emerged as a promising complementary method for post‐marketing drug safety surveillance. The EU‐ADR project, funded by the European Commission, is developing techniques that allow mining of EHRs for adverse drug events across different countries in Europe. Since mining on all possible events was considered to unduly increase the number of spurious signals, we wanted to create a ranked list of high‐priority events.

[1]  R Revol Núñez,et al.  [Aplastic anemia]. , 1970, Archivos Argentinos de Pediatria.

[2]  Richard Platt,et al.  Early adverse drug event signal detection within population‐based health networks using sequential methods: key methodologic considerations , 2009, Pharmacoepidemiology and drug safety.

[3]  Richard Platt,et al.  Active drug safety surveillance: a tool to improve public health , 2008, Pharmacoepidemiology and drug safety.

[4]  Bruce M Psaty,et al.  Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. , 2008, JAMA.

[5]  P. Noyce,et al.  Hospital Admissions Associated with Adverse Drug Reactions: A Systematic Review of Prospective Observational Studies , 2008, The Annals of pharmacotherapy.

[6]  M. Mockenhaupt,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  V. Balan,et al.  Inpatient Admissions for Drug-induced Liver Injury: Results from a Single Center , 2008, Digestive Diseases and Sciences.

[8]  X. Vidal,et al.  Epidemiology of aplastic anemia: a prospective multicenter study , 2008, Haematologica.

[9]  N. Pannu,et al.  An overview of drug-induced acute kidney injury , 2008, Critical care medicine.

[10]  Miriam C J M Sturkenboom,et al.  Adverse drug reaction‐related hospitalisations: a population‐based cohort study , 2008, Pharmacoepidemiology and drug safety.

[11]  D. Pollock,et al.  National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. , 2008, The Journal of pediatrics.

[12]  S. Factor,et al.  Failure of recognition of drug‐induced parkinsonism in the elderly , 2008, Movement disorders : official journal of the Movement Disorder Society.

[13]  S. Dursun,et al.  Neurological complications of psychiatric drugs: clinical features and management , 2008, Human psychopharmacology.

[14]  C. Richards,et al.  Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults , 2007, Annals of Internal Medicine.

[15]  M. Kulldorff,et al.  Early detection of adverse drug events within population‐based health networks: application of sequential testing methods , 2007, Pharmacoepidemiology and drug safety.

[16]  F. Martin,et al.  Associations of delirium with in-hospital and in 6-months mortality in elderly medical inpatients. , 2007, Age and ageing.

[17]  R. Aster,et al.  Drug-induced immune thrombocytopenia. , 2007, The New England journal of medicine.

[18]  Josip Car,et al.  Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005 , 2007, BMC clinical pharmacology.

[19]  W. Poewe,et al.  Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease , 2007, The Lancet Neurology.

[20]  A. Melander,et al.  Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care , 2007, The Annals of pharmacotherapy.

[21]  D. Franciotti Hospital admissions in Italy for liver and gastrointestinal diseases in the period 1999–2002: an epidemiological study , 2007, European journal of gastroenterology & hepatology.

[22]  E. Růžička,et al.  Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide , 2007, Journal of Neurology.

[23]  F. Andersohn,et al.  Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs , 2007, Annals of Internal Medicine.

[24]  Mark McClellan,et al.  Drug safety reform at the FDA--pendulum swing or systematic improvement? , 2007, The New England journal of medicine.

[25]  J. Gottschall,et al.  One center's experience: the serology and drugs associated with drug‐induced immune hemolytic anemia—a new paradigm , 2007, Transfusion.

[26]  Meredith Wadman,et al.  Experts call for active surveillance of drug safety , 2007, Nature.

[27]  J. Thundiyil,et al.  Evolving epidemiology of drug-induced seizures reported to a poison control center system , 2007, Journal of Medical Toxicology.

[28]  F. Hanefeld,et al.  Valproic acid-induced pancreatitis: 16 new cases and a review of the literature , 2007, Journal of Gastroenterology.

[29]  M. Matthews,et al.  Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. , 2007, Clinical therapeutics.

[30]  S. Gentile Extrapyramidal Adverse Events Associated With Atypical Antipsychotic Treatment of Bipolar Disorder , 2007, Journal of clinical psychopharmacology.

[31]  S. Gentile Nontricyclic antidepressants - Predictors of nonadherence , 2007 .

[32]  A. Antonini,et al.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease. , 2007, The New England journal of medicine.

[33]  I. Boyd,et al.  Risk Factors for Rhabdomyolysis with Simvastatin and Atorvastatin , 2006, Drug safety.

[34]  J. Montastruc,et al.  The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France , 2006, Pharmacoepidemiology and drug safety.

[35]  D. Pollock,et al.  National surveillance of emergency department visits for outpatient adverse drug events. , 2006, JAMA.

[36]  N. Young,et al.  Current concepts in the pathophysiology and treatment of aplastic anemia. , 2006, Blood.

[37]  R. Mullins,et al.  2. Anaphylaxis: diagnosis and management , 2006, The Medical journal of Australia.

[38]  Manfred Hauben,et al.  Data mining in pharmacovigilance: lessons from phantom ships , 2006, European Journal of Clinical Pharmacology.

[39]  Anandi V Law,et al.  Adverse Drug Reactions Among Children Over a 10-Year Period , 2006, Pediatrics.

[40]  Robert L Davis,et al.  FDA drug prescribing warnings: is the black box half empty or half full? , 2006, Pharmacoepidemiology and drug safety.

[41]  Jerry Avorn,et al.  Evaluating drug effects in the post-Vioxx world: there must be a better way. , 2006, Circulation.

[42]  Borje Darpo,et al.  Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline , 2006, Journal of clinical pharmacology.

[43]  N. Scheinfeld Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. , 2006, Journal of drugs in dermatology : JDD.

[44]  J. Vandenbroucke What is the best evidence for determining harms of medical treatment? , 2006, Canadian Medical Association Journal.

[45]  Miriam C.J.M. Sturkenboom,et al.  Adverse Drug Reaction-Related Hospitalisations , 2006, Drug safety.

[46]  P. Waller,et al.  Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactions. , 2006, British journal of clinical pharmacology.

[47]  D. Madigan,et al.  The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.

[48]  M. Vray,et al.  The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs. , 2005, Therapie.

[49]  A. Puech,et al.  Place relative des essais cliniques comparatifs et des suivis de cohorte dans l’évaluation préet post-AMM des médicaments , 2005 .

[50]  D. Wysowski,et al.  Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. , 2005, Archives of internal medicine.

[51]  G. Trifirò,et al.  Adverse drug events in emergency department population: a prospective Italian study , 2005, Pharmacoepidemiology and drug safety.

[52]  X. Vidal,et al.  Population-based drug-induced agranulocytosis. , 2005, Archives of internal medicine.

[53]  N. Yawalkar Drug-induced exanthems. , 2005, Toxicology.

[54]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[55]  J. Lexchin Drug withdrawals from the Canadian market for safety reasons, 1963–2004 , 2005, Canadian Medical Association Journal.

[56]  P. Waller,et al.  Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics (HES) database. , 2005, British journal of clinical pharmacology.

[57]  M. Egger,et al.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.

[58]  N. Winick,et al.  Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. , 2004, AJNR. American journal of neuroradiology.

[59]  S. Deitcher,et al.  The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma , 2004, Cancer.

[60]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[61]  E. Keohane Acquired Aplastic Anemia , 2004, American Society for Clinical Laboratory Science.

[62]  J. Brien,et al.  Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics. , 2004, British journal of clinical pharmacology.

[63]  Lehana Thabane,et al.  Application of data mining techniques in pharmacovigilance. , 2003, British journal of clinical pharmacology.

[64]  A. Berghöfer,et al.  The Antisuicidal and Mortality-Reducing Effect of Lithium Prophylaxis: Consequences for Guidelines in Clinical Psychiatry , 2003, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[65]  G. Sachs Unmet Clinical Needs in Bipolar Disorder , 2003, Journal of clinical psychopharmacology.

[66]  Nicholas Moore,et al.  Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole , 2003, Pharmacoepidemiology and drug safety.

[67]  B. Alldredge,et al.  Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings , 2003, Expert opinion on drug safety.

[68]  Joshua Borus,et al.  Adverse drug events in ambulatory care. , 2003, The New England journal of medicine.

[69]  Robert W. Platt,et al.  Delirium in Older Emergency Department Patients Discharged Home: Effect on Survival , 2003, Journal of the American Geriatrics Society.

[70]  T. Gillessen,et al.  Iatrogenic and toxic myopathies , 2003, Muscle & nerve.

[71]  M. Cesari,et al.  Adverse Drug Reactions as Cause of Hospital Admissions: Results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA) , 2002, Journal of the American Geriatrics Society.

[72]  A. Bate,et al.  Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs , 2002, European Journal of Clinical Pharmacology.

[73]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[74]  Sebastian Schneeweiss,et al.  Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study , 2002, European Journal of Clinical Pharmacology.

[75]  C. Nzerue,et al.  How to prevent, recognize, and treat drug-induced nephrotoxicity. , 2002, Cleveland Clinic journal of medicine.

[76]  R. Shah Drug‐induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity , 2002, Fundamental & clinical pharmacology.

[77]  K. Lechner,et al.  Management of adult immune thrombocytopenia. , 2001, Reviews in clinical and experimental hematology.

[78]  D J Graham,et al.  The role of databases in drug postmarketing surveillance , 2001, Pharmacoepidemiology and drug safety.

[79]  S. Schneeweiss,et al.  First results from an intensified monitoring system to estimate drug related hospital admissions. , 2001, British journal of clinical pharmacology.

[80]  J. Vandenbroucke,et al.  Oral contraceptives and the risk of venous thrombosis. , 2001, The New England journal of medicine.

[81]  B. Bannwarth,et al.  [Drug-induced and toxic myopathies]. , 2001, La Revue du praticien.

[82]  S. Shapiro,et al.  Epidemiological assessment of drug-induced disease , 2000, The Lancet.

[83]  P. Chyka,et al.  How many deaths occur annually from adverse drug reactions in the United States? , 2000, The American journal of medicine.

[84]  P Smyth,et al.  Statistical Methods in Medical Research Data Mining: Data Analysis on a Grand Scale? , 2022 .

[85]  N. Moore,et al.  Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability , 2000, European Journal of Clinical Pharmacology.

[86]  F. Haramburu,et al.  Admissions to hospital caused by adverse drug reactions: cross sectional incidence study , 2000, BMJ : British Medical Journal.

[87]  P. Padfield,et al.  Renal , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[88]  B. Wiholm,et al.  Drug‐attributed anaphylaxis , 1998, Pharmacoepidemiology and drug safety.

[89]  Munir Pirmohamed,et al.  Fortnightly review: Adverse drug reactions , 1998 .

[90]  D. Bonn,et al.  Adverse drug reactions remain a major cause of death , 1998, The Lancet.

[91]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[92]  I. Edwards,et al.  Adverse drug reactions: finding the needle in the haystack , 1997, BMJ.

[93]  L. Hughes-Davies,et al.  Severe adverse cutaneous reactions to drugs. , 1995, The New England journal of medicine.

[94]  J. Bigby Harrison's Principles of Internal Medicine , 1988 .

[95]  B. Jakubski [Acute toxic renal failure]. , 1983, Wiadomosci lekarskie.

[96]  Thomas F. DeRosa,et al.  PSYCHIATRIC , 1970 .

[97]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.

[98]  J. Roujeau,et al.  Drug-Induced Skin, Nail and Hair Disorders , 2007, Drug safety.

[99]  Munir Pirmohamed,et al.  Adverse drug reactions in hospitals: a narrative review. , 2007, Current drug safety.

[100]  Ayman A El Menyar Drug-induced myocardial infarction secondary to coronary artery spasm in teenagers and young adults. , 2006, Journal of postgraduate medicine.

[101]  R. Meyboom,et al.  Drug-Induced Immune Thrombocytopenia , 2004, Drug safety.

[102]  M. Arné-Bès Neuropathies médicamenteuses: mise a jour récente des données (1996 a 2003). , 2004 .

[103]  Giuseppe Curigliano,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[104]  M. Lindquist,et al.  Assessing the Impact of Drug Safety Signals from the WHO Database Presented in ‘SIGNAL’ , 2003, Drug safety.

[105]  M. Lindquist,et al.  Signal Selection and Follow-Up in Pharmacovigilance , 2002, Drug safety.

[106]  I. Edwards The Accelerating Need for Pharmacovigilance , 2000, Journal of the Royal College of Physicians of London.

[107]  R. Baldessarini,et al.  Reduced suicide risk during lithium maintenance treatment. , 2000, The Journal of clinical psychiatry.

[108]  Edwards Ir The accelerating need for pharmacovigilance. , 2000 .

[109]  J. George,et al.  Drug-induced thrombocytopenia: a systematic review of published case reports. , 1998, Annals of internal medicine.

[110]  S. R. Fine,et al.  ADVERSE DRUG REACTIONS , 2009, BMJ : British Medical Journal.